Figure 5.
Figure 5. Treatment with the palmitoylation inhibitor 2-bromopalmitate (2-BP) results in Syt VII–YFP retention in the TGN. NRK cells transduced with adenovirus expressing Lamp1-RFP (A, C, and D), GalT-RFP (B), Syt VII–YFP (A, B, and D), Syt VII (C/S)–YFP (C), or CFP-CD63 (D) were imaged by live confocal microscopy after being treated with 100 µM 2-BP or carrier (Control) for 15 h. (A) Syt VII–YFP is mistargeted to globular structures resembling the Golgi apparatus in 2-BP–treated cells. (B) The globular structures containing Syt VII–YFP in 2-BP–treated cells colocalize with the trans-Golgi marker GalT-RFP. (C) The localization of Syt VII (C/S)–YFP does not change upon treatment with 2-BP. (D) The localization of CFP-CD63 on lysosomes is not altered by 2-BP treatment. Bars, 6 µm.

Treatment with the palmitoylation inhibitor 2-bromopalmitate (2-BP) results in Syt VII–YFP retention in the TGN. NRK cells transduced with adenovirus expressing Lamp1-RFP (A, C, and D), GalT-RFP (B), Syt VII–YFP (A, B, and D), Syt VII (C/S)–YFP (C), or CFP-CD63 (D) were imaged by live confocal microscopy after being treated with 100 µM 2-BP or carrier (Control) for 15 h. (A) Syt VII–YFP is mistargeted to globular structures resembling the Golgi apparatus in 2-BP–treated cells. (B) The globular structures containing Syt VII–YFP in 2-BP–treated cells colocalize with the trans-Golgi marker GalT-RFP. (C) The localization of Syt VII (C/S)–YFP does not change upon treatment with 2-BP. (D) The localization of CFP-CD63 on lysosomes is not altered by 2-BP treatment. Bars, 6 µm.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal